The U.S. uterine fibroid treatment market is estimated to be valued at US$ 269.4 Mn in 2023 and is expected to exhibit a CAGR of 4.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Uterine fibroids are non-cancerous tumors that grow in or on the wall of the uterus. They are made up of muscle and fibrous tissue. Uterine fibroids are quite common and affect up to 80% of women by the age of 50. Symptoms include heavy or painful periods, pain in the pelvis or lower back, frequent urination, pain during sex, or a full feeling in the lower abdomen. Treatment options include medication, surgery, uterine fibroid embolization (UFE), high intensity focused ultrasound (HIFU) and magnetic resonance guided focused ultrasound (MRgFUS).

Market Dynamics:
The rising prevalence of uterine fibroids is a key driver fueling the growth of this market. According to the Uterine Fibroid Study conducted at the National Institutes of Health, around 70-80% of women develop uterine fibroids by the time they reach menopause. Furthermore, African American women are disproportionately affected, with up to 80% developing fibroids by age 50. The changing lifestyle and lack of physical activity have led to an increase in obesity rates which is another driver contributing to the higher risk of uterine fibroids. Additionally, growing awareness about treatment options and non-invasive procedures is encouraging more women to seek treatment. However, high costs associated with fibroid treatment procedures may hinder market growth over the forecast period.

SWOT Analysis
Strength: The U.S. uterine fibroid treatment market has strong growth potential due to the rising prevalence of uterine fibroids in women. Non-invasive treatment options help reduce complications and recovery time. Moreover, the development of advanced minimally invasive procedures provides long-term treatment and relief from symptoms.
Weakness: High cost of innovative treatment devices and procedures can restrict their adoption in the market. Lack of awareness about disease conditions and available treatment options among patients poses challenges.
Opportunity: Growing research into novel treatment approaches will expand the product portfolio. Rising healthcare expenditure in the U.S. creates opportunities for market players.
Threats: Stringent regulatory approvals for new treatment devices may delay their launch. Growing awareness about healthy lifestyles can lower prevalence of uterine fibroids over the long run.

Key Takeaways

The U.S. uterine fibroid treatment market is expected to witness high growth, exhibiting CAGR of 4.0% over the forecast period, due to increasing preference for minimally invasive procedures. These procedures such as MRI-guided focused ultrasound surgery and uterine artery embolization help preserve the uterus and avoid hysterectomy.

Regional analysis: The North America region currently dominates the U.S. uterine fibroid treatment market due to growing geriatric population, rising incidence of uterine fibroids, and presence of advanced healthcare facilities. Factors such as rising awareness about disease conditions and availability of advanced diagnostics and treatment will boost the Asia Pacific market.

Key players operating in the U.S. uterine fibroid treatment market are Blue Endo, Boston Scientific Corporation or its affiliates, CooperSurgical, Inc., Karl Storz SE Co. KG, Myovant Sciences GmbH (Sumitovant Biopharma Ltd.), Halt Medical, Inc. (Hologic, Inc.), LiNA Medical ApS, Merit Medical Systems, Olympus Corporation, and Richard Wolf GmbH. These players are focusing on new product launches and strategic collaborations for market expansion